ABSTRACT
Objective To evaluate the effectiveness and cost-effectiveness of the National PreCePT Programme (NPP) in increasing magnesium sulphate (MgSO4) in pre-term births.
Design A quasi-experimental before-and-after design
Setting Maternity units within NHS England and the AHSN network in 2018.
Participants Maternity units in England (n=137) who participated in the NPP.
Interventions NPP support which included the PReCePT QI toolkit and materials (pre-term labour proforma, staff training presentations, parent leaflet, posters for the unit, learning log), regional AHSN level support, and up to 90 hours funded backfill for a midwife ‘champion’ to lead implementation.
Main outcome measures MgSO4 post-implementation uptake compared to pre-implementation uptake. Implementation and lifetime costs were estimated.
Results Compared to pre-implementation estimates, the average MgSO4 uptake in 137 maternity units in England increased by 6.3 percentage points (95% CI 2.6 to 10.0 percentage points) to 83.1% post-implementation, accounting for unit size, maternal, baby, and maternity unit factors, time trends, and AHSN. Further adjustment for early or late initiation of NPP activities increased the estimate to 9.5 percentage points (95% CI 4.3 to 14.7 percentage points). From a societal and lifetime perspective, the health gains and cost-savings associated with the NPP effectiveness generated a net monetary benefit of £866 per preterm baby and the probability of the NPP being cost-effective was greater than 95%.
Conclusion This national QI programme was effective and cost-effective. National programmes delivered via coordinated regional clinical networks can accelerate uptake of evidence-based therapies in perinatal care.
WHAT IS ALREADY KNOWN ON THIS TOPIC Since 2015 the UK National Institute for Health and Care Excellence (NICE) has recommended administration of Magnesium Sulphate (MgSO4) for fetal neuroprotection in very preterm deliveries as a core part of maternity care. By 2017, only two-thirds of all eligible women in England were being given MgSO4, with wide regional variation. The PReCePT pilot study showed an increase in uptake from 21% (2012-2013) to 88% after the introduction of the tool in2015 in 5 units. The National PReCePT Programme (NPP) was rolled out in 2018 by the national network of Academic Health Science Networks with a target to increase MgSO4 administration in England to 85% by 2020.
WHAT THIS STUDY ADDS The study has shown that the nationwide implementation of the NPP, which provided a Quality Improvement (QI) toolkit and materials, cross unit AHSN regional level support, and funded backfill for a unit midwife ‘champion’ through local regional support was effective and cost-effective. Scaling-up of network supported QI programmes at national level can accelerate uptake of new therapies and promote improvements in perinatal care delivery.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was jointly funded by the National Institute for Health Research Applied Research Collaboration West (NIHR ARC West, core NIHR infrastructure funded: NIHR200181) and the AHSN Network funded by NHS England. The Health Foundation funded the health economics evaluation (Funder reference 557668). The views expressed are those of the authors and not necessarily those of the Health Foundation, NHS England, NHS Improvement, the NIHR or the Department of Health and Social Care.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The UK National Health Service Health Research Authority (HRA project ID: 260504) and the University of Bristol Faculty of Health Sciences Research Ethics Committee (FREC Ref: 84582) gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Anonymised individual-level data for this study comes from the NNRD. Our data sharing agreement with the NNRD prohibits sharing data extracts outside of the University of Bristol research team. The NNRD data dictionary is available online and copies of the Statistical Analysis Plan are available on available on the University of Bristols institutional repository (https://research-information.bris.ac.uk/en/projects/national-precept-prevention-of-cerebral-palsy-in-pre-term-labour-).
https://research-information.bris.ac.uk/en/projects/national-precept-prevention-of-cerebral-palsy-in-pre-term-labour-